An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer

Author： Sartor O.   Dineen M.K.   Perez-Marreno R.   Chu F.M.   Carron G.J.   Tyler R.C.  

Publisher： Elsevier

ISSN： 0090-4295

Source： Urology, Vol.62, Iss.2, 2003-08, pp. : 319-323

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Patient-reported experience with the Viadur 12-month leuprolide implant for prostate cancer

By Fowler J.E.   the Viadur Study Group  

Urology, Vol. 58, Iss. 3, 2001-09 ,pp. : 430-434

Elsevier

Access to resources Recommend Favorite

Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer

By Sharifi R.   Knoll L.D.   Smith J.   Kramolowsky E.  

Urology, Vol. 51, Iss. 2, 1998-02 ,pp. : 271-276

Elsevier

Access to resources Recommend Favorite

A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer 2

By McLeod D.   Zinner N.   Tomera K.   Gleason D.   Fotheringham N.   Campion M.   Garnick M.B.   for the Abarelix Study Group  

Urology, Vol. 58, Iss. 5, 2001-11 ,pp. : 756-761

Elsevier

Access to resources Recommend Favorite

Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer

By Fowler J.E.   Flanagan M.   Gleason D.M.   Klimberg I.W.   Gottesman J.E.   Sharifi R.  

Urology, Vol. 55, Iss. 5, 2000-05 ,pp. : 639-642

Elsevier

Access to resources Recommend Favorite

Three-month depot of goserelin acetate: clinical efficacy and endocrine profile

By del Moral P.F.   Dijkman G.A.   Debruyne F.M.J.   Witjes W.P.J.   Kolvenbag G.J.C.M.  

Urology, Vol. 48, Iss. 6, 1996-12 ,pp. : 894-900

Elsevier

Access to resources Recommend Favorite